trending Market Intelligence /marketintelligence/en/news-insights/trending/dgy96s7WowE7oCnW-Mu7KA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

BioTime closes acquisition of Asterias Biotherapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

BioTime closes acquisition of Asterias Biotherapeutics

Alameda, Calif.-based BioTime Inc. completed its acquisition of biotechnology company Asterias Biotherapeutics Inc.

Under the all-stock deal, Asterias shareholders received 0.71 share of BioTime for each Asterias share held. Asterias owns about 16.2% of the combined company.

Asterias Biotherapeutics has filed for the delisting of its common shares on NYSE American following completion of the deal.

Fremont, Calif.-based Asterias develops cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer.